At 52 weeks, the semaglutide group showed a statistically significant reduction in areal bone mineral density at the total hip (estimated treatment difference: -0.020 g/cm, p = 0.001, equating to approximately 2.6% loss) and at the lumbar spine (ETD: -0.018 g/cm, p = 0.007, approximately 2.1% loss)
Yes, Lexapro is FDA-approved to treat depression and anxiety, making it an excellent choice for people experiencing both conditions, which happens in about 60% of cases
The presence of food stimulates insulin secretion, which helps transport L-Carnitine into muscle cells
For women with obesity, hormonal changes during menopause can drive weight gain and increase the risk of a heart attack, said Mette Thomsen, group vice president and head of Global Medical Affairs at Novo Nordisk